Setrusumab (UX-143)
Osteogenesis Imperfecta
Phase 3Active (Partnered with Ultragenyx)
Key Facts
Indication
Osteogenesis Imperfecta
Phase
Phase 3
Status
Active (Partnered with Ultragenyx)
Company
About Mereo BioPharma
Mereo BioPharma is a UK-based biopharma founded in 2015 with a mission to deliver impactful therapies for rare diseases with limited treatment options. Its core strategy involves identifying, in-licensing, and developing late-stage clinical assets that have been deprioritized by larger pharmaceutical companies, leveraging deep industry relationships and a patient-centric approach. Key achievements include a foundational asset acquisition from Novartis, a transformative 2019 merger with OncoMed that secured a NASDAQ listing, and a strategic partnership with Ultragenyx for its lead osteogenesis imperfecta program.
View full company profileTherapeutic Areas
Other Osteogenesis Imperfecta Drugs
| Drug | Company | Phase |
|---|---|---|
| AGA2115 | Angitia Biopharmaceuticals | Phase 2 |